Euretos has developed in silico methodologies for Target Identification: the identification of (alternative) targets for a known indication. We perform an in silico perturbation analysis to identify proteins that can correct the dysregulation profile associated with the disease. As part of this procedure, Euretos continuously develops and expands molecular disease models as new data becomes available.
High Level Approach
Conceptually, our approach consists of two steps. In the first step, we will construct an in silico molecular disease model for the indication, based on public and/or private data.
A molecular disease model identifies for a specific disease the dysregulated genes, proteins and pathways as well as the underlying cell types and interactions between cell types that are dysregulated, to the extent that available data allows this.
In the second step, we perform a perturbation analysis for each candidate target using the disease model developed in the first step.
The purpose of the perturbation analysis is to identify targets that specifically modulate the genes that are dysregulated in the disease, as described by the disease model. Where possible, we take into account the mode of action and cell type specific effects of the target modulation, and aim to predict the extent to which the dysregulation associated with the disease is corrected. The different targets are ranked using a score that quantifies the degree of modulation of the disease genes.
Euretos will provide a list of targets ranked using our target-indication score. It builds the case for several target candidates, elaborates on the molecular drivers for each of the candidates and on the various evaluation criteria.
For three selected targets, we will provide a description of the disease and perturbation model, as well as the evidence supporting the target ranking in a human-readable report in the form of a research paper. The report will contain references and links to publicly available knowledge and data supporting the premise of the three target candidates.
Furthermore, the customer will be able to review the target/indications with the gene disease page and the gene detail page in the Euretos AI platform for a 1-month period